| Date Filed | Type | Description |
| 02/14/2013 |
SC 13G/A
| RA CAPITAL MANAGEMENT, LLC reports a 9.9% stake in Genta Incorporated |
| 02/14/2013 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 9.9% stake in Genta Incorporated |
| 02/12/2013 |
SC 13G/A
| Boxer Capital, LLC reports a 10% stake in Genta Incorporated |
| 01/29/2013 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 20% stake in Genta Incorporated |
| 08/02/2012 |
8-K
| Quarterly results |
| 07/30/2012 |
8-K
| Form 8-K - Current report |
| 07/27/2012 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review |
| 07/26/2012 |
8-K
| Form 8-K - Current report |
| 07/11/2012 |
ARS
| Form ARS - Annual Report to Security Holders |
| 06/22/2012 |
SC 13D/A
| WARRELL RAYMOND P JR reports a 24.3% stake in Genta Incorporated |
| 06/22/2012 |
SC 13D
| SIEGEL GARY reports a 9.2% stake in Genta Incorporated |
| 06/22/2012 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/18/2012 |
GN
| Genta Announces Agreement With FDA on Special Protocol Assessment of Phase 3 Trial of Tesetaxel as Initial Chemotherapy for Women With Metastatic Breast Cancer |
| 06/18/2012 |
GN
| Genta Incorporated to Present at 2012 BIO International |
| 06/15/2012 |
8-K
| Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce... |
| 06/15/2012 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 06/08/2012 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements |
| 05/31/2012 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/31/2012 |
GN
| Genta Initiates Randomized Trial of Tesetaxel as First-Line Therapy for Women With Recurrent Breast Cancer |
| 05/25/2012 |
8-K
| Other Events |
| 05/24/2012 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/22/2012 |
8-K
| Other Events, Financial Statements and Exhibits |
| 05/22/2012 |
GN
| Tesetaxel Results as Initial Chemotherapy for Women With Recurrent Breast Cancer to be Highlighted at ASCO |
| 05/14/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 05/14/2012 |
8-K
| Quarterly results |
| 05/14/2012 |
GN
| Genta Incorporated Reports First Quarter 2012 Financial Results |
| 05/08/2012 |
GN
| Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer |
| 04/24/2012 |
8-K
| Resignation/termination of a director |
| 04/24/2012 |
GN
| Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors |
| 04/20/2012 |
8-K
| Other Events |
| 03/29/2012 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 03/28/2012 |
10-K
| Annual Report for the period ended December 31, 2011 |
| 03/23/2012 |
8-K
| Resignation/termination of a director |
| 03/16/2012 |
8-K
| Form 8-K - Current report |
|